Research Capital…I think Dr. Uddin's following statement: "If this trend continues, we believe Theralase’s Ruvidar (TLD-1433) has the potential to be better than Merck’s Keytruda and expect Ruvidar to launch in 2026,”
....would have been more clear if stated: "If this trend continues, Ruvidar (TLD-1433) has the potential to be better than Merck's Keytruda and would expect Ruvidar to receive traditional approval in 2026, with the potential of launching significantly earlier via the AA pathway." JMHO & view of our current position.